Cromos Pharma, where the patients are

Articles Published in 2012

Bio-Rad to acquire MorphoSys's research & diagnostics antibody business

Tuesday, December 18, 2012 09:16 AM

MorphoSys, a German biotech focused on human antibodies, has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products.

More... »

CRF Health eCOA webinar series

FDA approves GSK's four-strain seasonal influenza vaccine

Monday, December 17, 2012 04:28 PM

The FDA has approved GlaxoSmithKline’s Fluarix Quadrivalent (influenza virus vaccine) for the immunization of adults and children (three years and older) to help prevent disease caused by seasonal influenza virus subtypes A and B contained in the vaccine.

More... »

Charlie Morris appointed to Almac’s clinical technologies executive team

Monday, December 17, 2012 04:01 PM

The Almac Group’s clinical technologies business unit has appointed Charlie Morris as vice president of new products and services. In this role, Morris will oversee the development of Almac’s IXRS technology and enhance the company’s metrics-based discipline to the software development process.

More... »

Promedior opens new office and labs in Lexington, Mass.

Monday, December 17, 2012 03:34 PM

Promedior, a clinical stage biotechnology company focused on fibrosis, is opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Mass.

More... »

Vivalis, Intercell merge to create Valneva

Monday, December 17, 2012 03:06 PM

The management boards of Vivalis, a biopharmaceutical company focused on cell-based solutions, and Intercell, a vaccine-biotechnology company, have agreed to the terms of a merger to create the newly-named Valneva, a European biotechnology company in vaccines and antibodies.

More... »

23andMe raises more than $50M in new financing

Monday, December 17, 2012 02:37 PM

23andMe, a personal genetics company based in Mountain View, Calif., has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.

More... »

Phenex, Janssen form research collaboration on autoimmune, inflammatory disorders

Monday, December 17, 2012 02:09 PM

Phenex Pharmaceuticals, a privately held drug discovery and development company based in Germany, has entered into an agreement with Janssen Biotech and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis and inflammatory bowel disease.

More... »

Teva, Handok to establish business venture in Korean pharma market

Monday, December 17, 2012 01:41 PM

Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, and Handok Pharmaceuticals, a pharmaceutical/healthcare company in Korea, have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately $14 billion.

More... »

UMCG initiates enrollment in RENEW trial for severe emphysema

Monday, December 17, 2012 12:31 PM

The University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC) in severe emphysema. 

More... »

Naurex completes $38M Series B financing

Monday, December 17, 2012 12:03 PM

Naurex, an Evanston, Ill.-based clinical-stage company focused on developing treatments for CNS disorders, has completed a $38 million Series B financing led by new investor Baxter Ventures. 

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs